GlassScriptPhysician profile
Cameron Stephenson
NPI 1790065738
$2,800.94
in general payments reported to CMS, 2019-2025
23 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $260 · 2023: $150 · 2024: $306 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,107 · Food and Beverage: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,106.53 |
| Food and Beverage | $906.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,269.67 | 2024-2025 | Spravato |
| Abbvie INC. | $262.37 | 2021-2025 | |
| Corium, LLC | $180.28 | 2022-2024 | Azstarys |
| Ucb, INC. | $171.48 | 2021-2024 | Nayzilam |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.01 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Vanda Pharmaceuticals INC. | $104.79 | 2025 | Fanapt |
| Alexion Pharmaceuticals, INC. | $86.04 | 2021-2025 | Ultomiris |
| Lilly USA, LLC | $74.06 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.45 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $56.15 | 2022-2023 | Farxiga |
| Arbor Pharmaceuticals, INC. | $41.61 | 2021-2022 | |
| Axsome Therapeutics, INC. | $35.62 | 2024-2025 | Auvelity |
| Catalyst Pharmaceuticals, INC. | $35.04 | 2024 | |
| Supernus Pharmaceuticals, INC. | $34.85 | 2021-2023 | Qelbree |
| Tris Pharma INC | $33.21 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $32.92 | 2021 | |
| Glaxosmithkline, LLC. | $32.56 | 2022 | |
| Alkermes, INC. | $26.41 | 2025 | Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $21.46 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $20.51 | 2025 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $18.67 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.92 | 2025 | Caplyta |
| Evoke Pharma, INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Stephenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.